Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$116.5M
67M shares
52-week range
$1.60 – $4.67
1% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.
www.microbotmedical.comNo one on the platform currently holds MBOT.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 24,560 | $49.1K |
| Execution date | Ratio |
|---|---|
| 2018-09-05 | 1-for-15reverse |
| 2016-05-09 | 1-for-12reverse |
No one on the platform has traded MBOT yet.
$GCTS $PLUG $MBOT I sometimes look at yahoo price target just for the sake of it. Yearly. I know yahoo is old and stale but surprisingly it has proved to be relevant for me in past. MBOT $7.X PLUG $4.X GCTS $3.X FWIW
View on StockTwits ↗$MBOT it's just about whether or not the surgeons will prefer to twist and push guide wires and catheters wearing a lead apron or perform the procedure like a video game free from radiation. Who knows. My guess is the latter.
View on StockTwits ↗$MBOT if we don't get a small re rating to 3, 3.5 or better pr through winter, i might call it quits
View on StockTwits ↗$MBOT this company's product is great and provides value. I like it
View on StockTwits ↗$MBOT Microbot Medical Inc. (NASDAQ: MBOT) scheduled an investor conference call for August 13, 2026, at 4:00 p.m. ET following the release of its Q2 2026 financial results on August 11, 2026
View on StockTwits ↗$MBOT … Acquisition of Certain Patents On July 28, 2026, the Company acquired certain patents and related technology and assets (collectively, the “Assets”) from Forge Medical Inc. (“Forge”), relating to Forge’s discontinued VasoStat Hemostasis device (“VasoStat”). VasoStat was designed to provide arterial compression at the puncture-site following catheterization procedures for the purpose of stopping bleeding and for use following radial and tibial catheterization procedures. The purchase price for the Assets is limited to potential royalties payable to Forge as, if and when the Company commercializes the Assets, based upon a formula set forth in the purchase agreement for the Assets, and in any event is limited to a maximum of $5,000...
View on StockTwits ↗$MBOT some interesting readings from the 10-q, which may or may not be new, I will check on it, posting 1 at a time: “Telemedicine capability – May serve as a platform for supporting tele-catheterization, carried out remotely by highly trained specialists. The Company’s research collaboration with Corewell Health™ has demonstrated the feasibility of using the LIBERTY® Endovascular Robotic System between separate and remote facilities in a coronary simulation model. The project assesses the feasibility of using the LIBERTY® Endovascular Robotic System to perform simulated cardiovascular interventional procedures across two sites within the Corewell Health™ system located 5 miles apart. The telesurgery feature of the LIBERTY® Endovascular Robotic System is still being evaluated and is not covered under the Company’s 510(k) clearance with the U.S. Food and Drug Administration (“FDA”).”
View on StockTwits ↗$MBOT I think the quarter was basically what they said it would be. Obviously, the problem is the revenue. Everyone wanted more, but 100% is nothing to shake a stick at. I'm thinking this reaction is because they plan to expand to the West Coast and into Europe. That will take a lot of cash. If the revenue seems to be coming in slower than wanted to offset that cost, then they will have to tap the ATM funding sooner than later. Dilution never goes over well with retail, even if it's for expansion.
View on StockTwits ↗$MBOT i dont get it. 100% increase and the stock drops. Was this a bad release? Anyone see numbers yet?
View on StockTwits ↗$MBOT bio's are a frickin disaster at the moment. Or should I say mine choice in Bio's
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $3M | +2392.7% | $-0.28 | $-0.31–$-0.24 | — | 2 |
| 2027 | $9M | +215.0% | $-0.30 | $-0.31–$-0.27 | — | 2 |
| 2028 | $24M | +169.7% | $-0.20 | $-0.23–$-0.18 | — | 2 |
| 2029 | $48M | +98.3% | $0.03 | $0.03–$0.03 | 54.0× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-11 | $-0.08 | $-0.08 | -4.3% |
| 2026-05-13 | $-0.08 | $-0.05 | +37.5% |
| 2026-03-26 | $-0.06 | $-0.04 | +33.3% |
| 2025-11-12 | $-0.06 | $-0.07 | -16.7% |
| 2025-08-12 | $-0.08 | $-0.10 | -25.0% |
| 2025-05-14 | $-0.13 | $-0.08 | +38.5% |
| 2025-03-25 | $-0.18 | $-0.20 | -11.1% |
| 2024-11-13 | $-0.17 |
| $-0.20 |
| -17.6% |
| $65M |
| — |
| NSPRInspireMD, Inc. | $0.94 | +11.88% | $44M | — |
| ORMPOramed Pharmaceuticals Inc. | $4.36 | -0.46% | $178M | — |
Source: Financial Modeling Prep · peers by sector/industry